Nuyten Dimitry SA
Known title: Chief Medical OfficerCIK: 0001776564
Associated companies
Transaction History
| RCUS | ▼ Sell | Tax Withholding | 7,856 | $126K | 12/15/2024 | View on chart |
| RCUS | ▼ Sell | Tax Withholding | 5,385 | $97K | 9/15/2024 | View on chart |
| RCUS | ▲ Buy | Grant | 28,000 | $0 | 1/23/2024 | View on chart |
| RCUS | ▼ Sell | Other | 1,540 | $28K | 12/19/2023 | View on chart |
| RCUS | ▼ Sell | Other | 1,507 | $27K | 12/18/2023 | View on chart |
| RCUS | ▼ Sell | Other | 3,708 | $76K | 9/18/2023 | View on chart |
| RCUS | ▲ Buy | Grant | 34,000 | $0 | 1/23/2023 | View on chart |
| RCUS | ▲ Buy | Grant | 42,500 | $0 | 8/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Arcus Biosciences gets JP Morgan coverage, adds grant program
JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.
Arcus Biosciences gets JP Morgan coverage, adds grant program. JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.